Physician profile
Robert M Boldy
NPI 1063507382
$4,313.73
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,598 · 2020: $756 · 2021: $767 · 2022: $175 · 2023: $17.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $805.16 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $491.87 | 2019-2021 | |
| Amgen INC. | $340.99 | 2019-2022 | |
| Dexcom, INC. | $277.99 | 2021 | |
| Novo Nordisk INC | $255.24 | 2019-2023 | Rybelsus, Ozempic |
| Regeneron Healthcare Solutions, INC. | $250.00 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $249.20 | 2019 | |
| Merck Sharp & Dohme LLC | $217.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.03 | 2019-2021 | |
| Glaxosmithkline, LLC. | $147.14 | 2019-2021 | |
| Hologic Sales and Service, LLC | $125.00 | 2019 | |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Intercept Pharmaceuticals, INC. | $120.52 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $117.01 | 2022 | |
| Ironshore Pharmaceuticals INC. | $114.41 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $104.58 | 2019 | |
| Sanofi-Aventis U.S. LLC | $100.00 | 2019 | |
| Alkermes, INC. | $99.71 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.23 | 2019 | |
| Sanofi Pasteur INC. | $32.62 | 2019-2020 | |
| Pfizer INC. | $26.04 | 2022 | |
| Mannkind Corporation | $21.61 | 2019 | |
| Abbvie INC. | $18.66 | 2022 | |
| Phadia US INC. | $12.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Boldy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.